| Dr Bryan Duepner, DO | |
|
225 Clarkson Rd, Ellisville, MO 63011-2278 | |
| (636) 685-7715 | |
| (314) 590-5944 |
| Full Name | Dr Bryan Duepner |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 7 Years |
| Location | 225 Clarkson Rd, Ellisville, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861912826 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 2017018399 (Missouri) | Secondary |
| 207Q00000X | Family Medicine | 2020011648 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fenton Family Physicians Llc | 5799084091 | 3 |
| Rehabilitation Professionals Inc | 8224923800 | 169 |
News Archive
It takes a village to keep a pregnant woman at her healthiest, a new University of Michigan study shows. The study compared African American and European American women and women of lower and higher socioeconomic status to see what effects communalism, or a strong sense of community, had on African American women and women of lower socioeconomic status.
As part of a series about Americans' response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans' views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.
After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 2 days ago
| Entity Name | Westglen Family Physicians, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114957354 PECOS PAC ID: 3678506102 Enrollment ID: O20050915000398 |
News Archive
It takes a village to keep a pregnant woman at her healthiest, a new University of Michigan study shows. The study compared African American and European American women and women of lower and higher socioeconomic status to see what effects communalism, or a strong sense of community, had on African American women and women of lower socioeconomic status.
As part of a series about Americans' response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans' views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.
After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 2 days ago
| Entity Name | Fenton Family Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679939128 PECOS PAC ID: 5799084091 Enrollment ID: O20160506001655 |
News Archive
It takes a village to keep a pregnant woman at her healthiest, a new University of Michigan study shows. The study compared African American and European American women and women of lower and higher socioeconomic status to see what effects communalism, or a strong sense of community, had on African American women and women of lower socioeconomic status.
As part of a series about Americans' response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans' views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.
After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bryan Duepner, DO 2345 Dougherty Ferry Rd, Saint Louis, MO 63122-3313 Ph: (314) 966-9491 | Dr Bryan Duepner, DO 225 Clarkson Rd, Ellisville, MO 63011-2278 Ph: (636) 685-7715 |
News Archive
It takes a village to keep a pregnant woman at her healthiest, a new University of Michigan study shows. The study compared African American and European American women and women of lower and higher socioeconomic status to see what effects communalism, or a strong sense of community, had on African American women and women of lower socioeconomic status.
As part of a series about Americans' response to the H1N1 flu outbreak, the Harvard Opinion Research Program at the Harvard School of Public Health is releasing a national poll that focuses on Americans' views and concerns about the potential for a more severe outbreak of Influenza A (H1N1) in the fall or winter. The polling was done June 22-28, 2009.
Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.
After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.
› Verified 2 days ago
William Markus Koeppel, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 225 Clarkson Rd, Ellisville, MO 63011 Phone: 706-865-4001 Fax: 706-865-6268 | |
Dr. Cynthia J Poelker, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 225 Clarkson Rd, Ellisville, MO 63011 Phone: 636-230-5050 Fax: 636-230-5057 | |
Dr. Jessee Crane, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 233 Clarkson Rd, Ellisville, MO 63011 Phone: 636-256-8644 | |
Barbara Anne O'brien, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 225 Clarkson Rd, Ellisville, MO 63011 Phone: 636-685-7715 Fax: 314-590-5916 | |
Dr. Jane Clara Gelfand, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 15838 Fountain Plaza Dr, Ellisville, MO 63011 Phone: 636-484-5220 | |
Lori Ann Orso, Family Medicine Medicare: Medicare Enrolled Practice Location: 233 Clarkson Rd, Ellisville, MO 63011 Phone: 636-256-8644 | |
Dr. Clarissa Jara Allen, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 225 Clarkson Rd, Ellisville, MO 63011 Phone: 636-230-5050 Fax: 636-230-5057 |